Skip to main content
NVETOTCinactive

Nexvet Biopharma plc

Biopharma developer (SEC filing verified)·Phase 3·CEO: Mark Heffernan, Ph.D.
OncologyPainMusculoskeletal

NVET evidence brief

What we can confirm

No verified snapshot fields are available yet.

What it means

The company data is ready for cross-source review; unsupported conclusions remain unknown.

What to watch

Watch the next source-backed data update.
BioSniper AIPage evidence connected

Prepared research question

What matters most for NVET—catalysts, financial risk and supporting evidence?

Run cited research

Traceable citations · Unknowns marked

6.2/10

BioSniper Score

Based on 4 of 6 signals

Market Cap

—

Cash Runway

8.2 mo

Lead Asset

frunevetmab (Phase 2)

Next Catalyst

—

Financial data as of Mar 31, 2017.

Tracking 2 pipeline candidates for Nexvet Biopharma plc.

Run Nexvet Biopharma plc through your own thesis

Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.

Your protocol can:

  • Turn available Nexvet Biopharma plc facts into screen rules or deeper checks
  • Show cited findings, blockers, and unresolved evidence together
  • Save the logic and rerun it as the company evidence changes
Run a thesis on this company — freeRun a thesis on this company

Score breakdownBased on 4 of 6 signals · derived from public data

Cash Runway2.3

8.2 months

Financial Health9.5

D/E 0.18

Pipeline Maturity8.5

Lead: Phase 3

Pipeline Breadth4.6

2 candidates

Catalyst MomentumN/A

No upcoming catalysts tracked

Insider SignalN/A

No insider transactions in the last 180 days

Runway

Run my thesis on this company

Pipeline

Run my thesis on this company

Financials

Run my thesis on this company

Frequently asked questions

What is Nexvet Biopharma plc's lead drug candidate?

Nexvet Biopharma plc's most advanced tracked candidate is frunevetmab (Phase 2) for chronic pain associated with osteoarthritis in cats.

Who is the CEO of Nexvet Biopharma plc?

Mark Heffernan, Ph.D. is the chief executive officer of Nexvet Biopharma plc (NVET).

What therapeutic areas does Nexvet Biopharma plc focus on?

Nexvet Biopharma plc develops therapies across Oncology, Pain, Musculoskeletal.

925 companies232,681 SEC filings21,419 clinical trials100% citation-verification pass rate (7d)How we verify →

The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.